Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
Abstract
Over the last few months, there has been a passionate debate within the scientific community on the risks and the benefits of the vaccines against COVID-19 disease. Reporting relative risk reductio...
Overview
CoChat Summary
TL;DR
This editorial argues that COVID-19 vaccine results should be reported using both relative risk reduction (RRR) and absolute risk reduction (ARR), because the two measures differ by orders of magnitude and can lead to different risk/benefit conclusions. The author concludes that RRR better expresses the intrinsic protective efficacy of a vaccine, while ARR (and its derivative NNV) is time- and baseline-risk-dependent and better suited to decision makers comparing vaccination effectiveness across populations.
Key findings
- The 95% RRR reported for BNT162b2 (Pfizer-BioNTech) in its phase 3 trial corresponds to an ARR of only 0.85%, and an NNV of 119.
- ARR and NNV are time-dependent: 5–6 month updates on BNT162b2 and mRNA-1273 (Moderna-NIH) showed ARR increasing to 3.7% and 4.9%, corresponding to NNVs of 27 and 21, respectively.
- By comparison, polypill primary prevention had an NNT of 36–57 to prevent an acute cardiovascular event over 5 years (a period ~30 times longer than COVID-19 phase 3 studies); assuming an approximately constant slope of event-free survival curves, the author estimates a first-months NNT of roughly 1000, far higher than the NNV of 119 for BNT162b2.
- ARR is not an intrinsic property of a vaccine but a predictor of real-world effectiveness resulting from the interaction between vaccine efficacy (RRR) and baseline population risk; the higher the viral circulation, the higher the ARR.
Methods
- Design: editorial/commentary (Expert Review of Vaccines, pages 873–875); no new primary data collected.
- Data: narrative synthesis of published phase 3 COVID-19 vaccine trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, rAd26/rAd5, NVX-CoV2373, CoronaVac, inactivated vaccines), influenza vaccine literature, the Seven Countries Study, and polypill cardiovascular prevention studies.
- Analysis: conceptual comparison of RRR versus ARR/NNV, including a hypothetical worked example (Figure 1) of a vaccine with 75% RRR showing ARR of 12% versus 24% depending on baseline risk and follow-up duration.
Limitations
- The author explicitly states the polypill comparison is an "oversimplified model," and notes that factors such as progressive reduction in vulnerable subjects, immunity decline, and emerging escape variants can modify vaccine effectiveness over time.
- The author states that the unusual conditions under which COVID-19 vaccines were tested (especially social distancing, which cannot be maintained long-term) may make ARR an unreliable "effectiveness predictor" of vaccination at population level.
- Evident from the text: this is a non-systematic editorial without formal search strategy, meta-analysis, or quantitative synthesis; numerical comparisons rely on cited trials and a hypothetical figure rather than new empirical analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 12 Not checked · 10 Own results and interpretations
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Reporting relative risk reduction (RRR), as usually done in phase 3 studies, does not consider the background risk of being infected and becoming ill with COVID-19, which varies between population and over time.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Using one of the two measures to estimate the risk/benefit ratio would lead to different conclusions.”
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“The two indices, being conceptually different, are of different order of magnitude () [Citation3–10]; for example, the 95% RRR for BNT162b2 (Pfizer-BioNTech) vaccine [Citation3] corresponds to 0.85% ARR [Citation1].”
What the sources say
- Not matchedcites Citation3
This doesn’t read as a citation we can look up.
- Not matchedcites Citation1
This doesn’t read as a citation we can look up.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“The above mentioned fall of risk reduction indices of BNT162b2 vaccine could therefore be, at least in part, correlated to the very short duration of the study [Citation3] (median value 2 months).”
What the sources say
- Not matchedcites Citation3
This doesn’t read as a citation we can look up.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The unusual conditions under which COVID-19 vaccines have been tested (in particular social distancing, that cannot be maintained for a long time), possibly makes ARR an unreliable ‘effectiveness predictor’ of vaccination at population level.”
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
11 more claims
Create a free account to see all 22 claims and every source verdict.
- It may state two separate claims as one. 5
- Probably not a substantial claim. 1
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 3×
“very short duration of the study [3] (median value 2 months).”
BackgroundInfluentialEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“0 119 (Pfizer-BioNtech) mRNA1273 [4] 1.”
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397 · cited 1×
“8 90 (Astra Zeneca – Oxford) Ad26CoV2S [6] 1.”
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789 · cited 1×
“As an example, efficacy and effectiveness of influenza vaccines are estimated on studies lasting the whole influenza season (5– 6 months), considerably longer than COVID-19 vaccine studies [11], and are tested in a completely different background situation, with no or limited use of mitigation procedures at population…”
BackgroundLogunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747 · cited 1×
“9 84 (Johnson & Johnson) GamCovidVac [7] 0.”
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640 · cited 1×
“Nevertheless, very recent papers reporting five to six-months update on BNT162b2 and mRNA1273 (ModernaNIH) vaccines [14,15], actually gives the measure of the dependence of ARR on the time of observation, showing an increase of ARR up to 3.”
BackgroundSix Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085
Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01429-x · Cited by 898
Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M. M., Abdulrazzaq, N., Al Nusair, M., Hassany, M., Jawad, J. S., Abdalla, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.8565 · Cited by 776
Cited by
Valenzuela-Avilés, P., Torrealba, D., Figueroa, C., Mercado, L. A., Dixon, B., Conejeros, P., & Gallardo, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019404 · Cited by 40
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19
England, C., TrejoMartinez, J., PerezSanchez, P., Karki, U., & Xu, J. (2023) · Life · doi:10.3390/life13030617 · Cited by 27
“Studies have showed that this subunit vaccine was about 90% effective in preventing SARS-CoV-2 infections [74](Centers for Disease Control and Prevention, CDC, USA), which is similar to the efficacy of Moderna (94%) and Pfizer (95%) and better than Johnson & Johnson (66%) [75].”
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?
Quinn, G. A., Connolly, R., ÓhAiseadha, C. O., Hynds, P. D., Bagus, P., Brown, R. B., Cáceres, C. F., Craig, C. E. H., Connolly, M., Domingo, J. L., et al. (2025) · International Journal of Public Health · doi:10.3389/ijph.2025.1607727 · Cited by 27
“These ARR results were reported alongside the RRR results and noted by several researchers at the time [261, 265 – 267].”
Dutcher, E. G., Epel, E. S., Mason, A. E., Hecht, F. M., Robinson, J. E., Drury, S. S., & Prather, A. A. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2956 · Cited by 20
Larkin, A., Waitzkin, H. B., Fassler, E. A., & Nayar, K. R. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063525 · Cited by 10
Metadata
- Authors
- Marabotti, C.
- Affiliations
- Azienda USL Toscana Nord Ovest (IT)
- Corresponding author
- Marabotti, Claudio
- ORCID
- Marabotti, Claudio
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2022-04-19
- Volume
- 21
- Issue
- 7
- Pages
- 873-875
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- PMC
- PMC9115787
- OpenAlex
- W4223996786
- Cited by
- 13
- References
- 15
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 7
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Review of Vaccines (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- London School of Hygiene and Tropical Medicine
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- COVID-19 vaccines, vaccine efficacy, vaccine effectiveness, absolute risk reduction, relative risk reduction, risk-benefit assessment
- MeSH terms
- COVID-19, COVID-19 Vaccines, Humans, Influenza, Human, Influenza Vaccines, Risk, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. https://app.cochat.ai/papers/10.1080/14760584.2022.2067531
- The paper
- Marabotti, C. (2022). Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. Expert Review of Vaccines. https://doi.org/10.1080/14760584.2022.2067531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.